title: Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
abstract: The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML is still evaluated using prognostic scores developed in the chemotherapy and interferon era. The present work describes a new prognostic score that is superior to the Sokal and Euro scores both in its prognostic ability and in its simplicity. The predictive power of the score was developed and tested on a group of patients selected from a registry of 2060 patients enrolled in studies of first-line treatment with imatinib-based regimes. The EUTOS score using the percentage of basophils and spleen size best discriminated between high-risk and low-risk groups of patients, with a positive predictive value of not reaching a CCgR of 34%. Five-year progression-free survival was significantly better in the low- than in the high-risk group (90% vs 82%, P = .006). These results were confirmed in the validation sample. The score can be used to identify CML patients with significantly lower probabilities of responding to therapy and survival, thus alerting physicians to those patients who require closer observation and early intervention.
authors.affiliation: Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, München, Germany. has@ibe.med.uni-muenchen.de
authors.forename: Joerg
authors.initials: J
authors.lastname: Hasford
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.forename: Verena
authors.initials: V
authors.lastname: Hoffmann
authors.forename: Joelle
authors.initials: J
authors.lastname: Guilhot
authors.forename: Susanne
authors.initials: S
authors.lastname: Saussele
authors.forename: Gianantonio
authors.initials: G
authors.lastname: Rosti
authors.forename: François
authors.initials: F
authors.lastname: Guilhot
authors.forename: Kimmo
authors.initials: K
authors.lastname: Porkka
authors.forename: Gert
authors.initials: G
authors.lastname: Ossenkoppele
authors.forename: Doris
authors.initials: D
authors.lastname: Lindoerfer
authors.forename: Bengt
authors.initials: B
authors.lastname: Simonsson
authors.forename: Markus
authors.initials: M
authors.lastname: Pfirrmann
authors.forename: Rudiger
authors.initials: R
authors.lastname: Hehlmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001491:Basophils / Q000473:pathology; D001549:Benzamides; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D010879:Piperazines / Q000008:administration & dosage*; D011237:Predictive Value of Tests; D011379:Prognosis; D011743:Pyrimidines / Q000008:administration & dosage*; D012042:Registries / Q000706:statistics & numerical data; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D013154:Spleen / Q000473:pathology; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate